PD184352 (CI-1040)

Catalog No.S1020

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Cited by 78 Publications

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Cell, 2016, 10.1016/j.ccell.2016.01.006

PubMed: 26859455 ( click the link to review the publication )

Cancer Discov, 2013, 3(9):1058-71

PubMed: 23744832 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 74(5):1086-1102.e5

PubMed: 31101498 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2358-2372

PubMed: 31461652 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

EMBO J, 2018, 37(1):19-38

PubMed: 29150432 ( click the link to review the publication )

PLoS Biol, 2018, 16(5):e2003619

PubMed: 29771909 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):320-336

PubMed: 29263201 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )
J Hematol Oncol, 2017, 10(1):19

PubMed: 28100259 ( click the link to review the publication )

FASEB J, 2017, 31(5):1903-1915

PubMed: 28174207 ( click the link to review the publication )

Antiviral Res, 2017, 142:178-184

PubMed: 28377100 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Methods Mol Biol, 2017, 1487:163-174

PubMed: 27924566 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):658-68

PubMed: 26189368 ( click the link to review the publication )

Drug Metab Dispos, 2016, 44(5):665-71

PubMed: 26953171 ( click the link to review the publication )

Oncol Lett, 2016, 11(1):99-104

PubMed: 26870175 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(10):1961-8

PubMed: 27249593 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Anim Reprod Sci, 2015, 161:47-57

PubMed: 26307658 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

eNeuro, 2015, 2(5)

PubMed: 26730399 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3016-31

PubMed: 24937430 ( click the link to review the publication )

EMBO Mol Med, 2014, 7(1):102-23

PubMed: 25550395 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

FASEB J, 2014, 28(10):4551-62

PubMed: 25008089 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )
BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114389

PubMed: 25486532 ( click the link to review the publication )

J Clin Invest, 2013, 123(11):4786-98

PubMed: 24216509 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Dis Model Mech, 2013, 6(2):521-9

PubMed: 22996645 ( click the link to review the publication )

PLoS One, 2013, 8(10):e76505

PubMed: 24124570 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68378

PubMed: 23874604 ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

Oncogene, 2012, 32(38):4480-9

PubMed: 23108403 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(4):R111

PubMed: 22817771 ( click the link to review the publication )

Neoplasia, 2012, 14(4):283-96

PubMed: 22577344 ( click the link to review the publication )

J Biol Chem, 2012, 288(6):4174-93

PubMed: 23255592 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27863-75

PubMed: 22685289 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(6):1056-73

PubMed: 22570334 ( click the link to review the publication )

Int J Parasitol, 2012, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )

J Cell Biochem, 2012, 113(1):360-71

PubMed: 21928324 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

J Exp Med, 2011, 208(9):1889-900

PubMed: 21825016 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(39):16392-7

PubMed: 21930937 ( click the link to review the publication )

Cell Death Dis, 2011, 2:e124

PubMed: 21368895 ( click the link to review the publication )

Neoplasia, 2011, 13(2):154-66

PubMed: 21403841 ( click the link to review the publication )
Dis Model Mech, 2011, 4(3):393-9

PubMed: 21263000 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

Toxicol Sci, 2011, 123(2):542-9

PubMed: 21742783 ( click the link to review the publication )

Front Physiol, 2011, 2:71

PubMed: 22028692 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features

First MEK inhibitor to begin clinical development.

Targets

MEK1 ^[1] (Cell-free assay)	MEK2 ^[1] (Cell-free assay)
17 nM	17 nM

In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. ^[1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. ^[2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. ^[3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
H9	M{DUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzVUmxtUUN3ME2wMlAzOjd4IN88US=>	NI\QbopUSU6JRWK=
CHP-212	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMEK4PFUh\|ryP	MV7TRW5ITVJ?
EoL-1-cell	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMESxOVIh\|ryP	MX\TRW5ITVJ?
DU-4475	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;LV4hKSzVyPUCuNFc2QTlizszN	MmG3V2FPT0WU
MMAC-SF	NYSyfJpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnxTWM2OD1yLkGwPVc1KM7:TR?=	NEi5VZVUSU6JRWK=
AGS	NH\HUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrTTWM2OD1yLkGxO\|E{KM7:TR?=	NVXUUXczW0GQR1XS
M14	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMUW0Olgh\|ryP	MnLWV2FPT0WU
CP50-MEL-B	MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3GTWM2OD1yLkG3NlU1KM7:TR?=	NWDOdJRwW0GQR1XS
C32	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3NTWM2OD1yLkG5NFczKM7:TR?=	NV7DOVFGW0GQR1XS
KMOE-2	NV;QdGVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkC4TWM2OD1yLkG5O\|k2KM7:TR?=	MnvxV2FPT0WU
A101D	NYXJd2xwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mny2TWM2OD1yLkKxOEDPxE1?	M1y1TnNCVkeHUh?=
KM12	M3L6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfVepk3UUN3ME2wMlI1ODV5IN88US=>	MmPPV2FPT0WU
HSC-4	NWPtN4N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HudmlEPTB;MD6yOFM6PSEQvF2=	M{GzTHNCVkeHUh?=
NOMO-1	M3P1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELxZYRKSzVyPUCuNlU4PDJizszN	NEXFWJpUSU6JRWK=
MZ7-mel	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\XVGw4UUN3ME2wMlI3OzRizszN	M3Ti[XNCVkeHUh?=
ACN	M3j5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMk[3N\|ch\|ryP	M{\WNXNCVkeHUh?=
MEL-HO	NYPMSYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2mzTGlEPTB;MD6yO\|Y2OiEQvF2=	MnGxV2FPT0WU
BHT-101	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTkTWM2OD1yLkK4OlA3KM7:TR?=	NYrrd3NvW0GQR1XS
SK-MEL-28	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwM{C0NFkh\|ryP	MofkV2FPT0WU
KG-1	NIWwUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HmTWlEPTB;MD6zNFY3QCEQvF2=	M365enNCVkeHUh?=
COLO-679	NVzh[lNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXSb\|JKSzVyPUCuN\|I4OiEQvF2=	Mm\EV2FPT0WU
SK-MEL-24	M1zWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPBNFFKSzVyPUCuN\|I5OTNizszN	MXLTRW5ITVJ?
G-361	NVTTU4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\jTWM2OD1yLkO2O\|k2KM7:TR?=	MXjTRW5ITVJ?
KY821	NV3PU3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYj5[JFqUUN3ME2wMlM4QTFizszN	NI\He\|RUSU6JRWK=
KASUMI-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULmV3czUUN3ME2wMlM6QSEQvF2=	Ml\JV2FPT0WU
HL-60	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPxfWJKSzVyPUCuOFEyODdizszN	NUjSSGFSW0GQR1XS
K5	NYP2SI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;jdZpKSzVyPUCuOFMyOTdizszN	NHzE[\|VUSU6JRWK=
KU812	M1jvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHCbpp5UUN3ME2wMlQ2Ojl7IN88US=>	NWXNZmNpW0GQR1XS
SH-4	NIjBeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHOXVhKSzVyPUCuOFYzPTZizszN	MWPTRW5ITVJ?
HTC-C3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moj0TWM2OD1yLkS2OVMyKM7:TR?=	M3y4b3NCVkeHUh?=
CP66-MEL	M2Hpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7nSGJKSzVyPUCuOFg5ODlizszN	NYXRVXpIW0GQR1XS
WM-115	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHqxTINKSzVyPUCuOFkzPTdizszN	MXXTRW5ITVJ?
A2780	M1rKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\GPGlEPTB;MD60PVgzOyEQvF2=	MoP0V2FPT0WU
P12-ICHIKAWA	NYLi[GxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDUSXhKSzVyPUCuOlEzOjFizszN	NWe0dWFQW0GQR1XS
HMV-II	NHfCSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwNkS0OlUh\|ryP	NF7IZoxUSU6JRWK=
HT-144	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPZVI1KSzVyPUCuOlQ3PTdizszN	MV3TRW5ITVJ?
LB2518-MEL	NEPPfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TJV2lEPTB;MD63NVY{OiEQvF2=	NFHoS\|VUSU6JRWK=
NCI-SNU-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorTTWM2OD1yLke1OFM{KM7:TR?=	NFHoZopUSU6JRWK=
C2BBe1	M3HNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwOEGwNlMh\|ryP	MXXTRW5ITVJ?
PSN1	NV\uVVdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvOTWM2OD1yLkm2NVk3KM7:TR?=	NX;J[JlVW0GQR1XS
UACC-257	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwOU[0O\|Mh\|ryP	NHnFNHpUSU6JRWK=
RVH-421	M37YfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1L5bmlEPTB;MD65O\|E5KM7:TR?=	MnPPV2FPT0WU
GP5d	NGjDfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLwcVV3UUN3ME2wMlk5OzB6IN88US=>	MYfTRW5ITVJ?
TYK-nu	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjVd3hYUUN3ME2xMlA{OTd{IN88US=>	M2jRNnNCVkeHUh?=
SK-N-AS	NIHqPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHUTWM2OD1zLkC3PVQ4KM7:TR?=	NECyVlJUSU6JRWK=
SW620	NX7tOlBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\MTm5KSzVyPUGuNVM2OzRizszN	MkO2V2FPT0WU
HuP-T4	NVnVZol5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTFwMUizOVkh\|ryP	M4TuZ3NCVkeHUh?=
A549	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF22NJhKSzVyPUGuNVk2PzZizszN	MmXIV2FPT0WU
Mewo	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTFwMkCyO\|Yh\|ryP	M1jlOHNCVkeHUh?=
ONS-76	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVm2XVVHUUN3ME2xMlIzODR7IN88US=>	M1:2THNCVkeHUh?=
SK-MEL-1	NHO2boxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TkOWlEPTB;MT6yN\|QyQSEQvF2=	NUDZS2dtW0GQR1XS
RCM-1	NET6dnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4qxZ2lEPTB;MT6yOFA1PyEQvF2=	MoqzV2FPT0WU
H-EMC-SS	M2D0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTSeVhKSzVyPUGuNlk3ODhizszN	MXXTRW5ITVJ?
NCI-H2291	NEjrbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTFwM{K1N\|Yh\|ryP	NES3UHlUSU6JRWK=
SW1463	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTFwM{O3NlEh\|ryP	MXfTRW5ITVJ?
LS-411N	NFHLWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrHWmFKSzVyPUGuOFA2OTdizszN	MVHTRW5ITVJ?
BV-173	M3zlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHoTWM2OD1zLkS0NFE2KM7:TR?=	MW\TRW5ITVJ?
LS-513	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nWWWlEPTB;MT60OVE6OiEQvF2=	NYnGb5pGW0GQR1XS
LoVo	NEnS[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXmybGdiUUN3ME2xMlQ3Ozl7IN88US=>	NFfIfItUSU6JRWK=
HO-1-N-1	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzoeoE5UUN3ME2xMlUyPjN2IN88US=>	NHjqeWZUSU6JRWK=
ML-2	M4rBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFwNUK4Olgh\|ryP	M{nSUXNCVkeHUh?=
NCI-H1437	NXvRZoU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTFwNUWyO\|Uh\|ryP	NWrTWpJ2W0GQR1XS
SW1116	NHPKXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjrNGFlUUN3ME2xMlU3Ozl6IN88US=>	MmToV2FPT0WU
A4-Fuk	Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPkNVZQUUN3ME2xMlU4ODR3IN88US=>	NWXISpRbW0GQR1XS
HD-MY-Z	NELyfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DmTGlEPTB;MT61O\|M4PiEQvF2=	MYPTRW5ITVJ?
SK-MEL-2	NUf1R21vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTFwNUe0OVkh\|ryP	NH3L[5pUSU6JRWK=
RT-112	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjYPFFkUUN3ME2xMlU5QTV{IN88US=>	Ml\hV2FPT0WU
COLO-829	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPJb4xKSzVyPUGuOlIzOzJizszN	MmjXV2FPT0WU
OVCAR-5	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPWNoJKSzVyPUGuO\|c3QDdizszN	MXXTRW5ITVJ?
NB69	NYDPZ5BCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXmzUmx4UUN3ME2xMlc5PDZ7IN88US=>	NIW3V\|lUSU6JRWK=
NCI-H292	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXlVWVbUUN3ME2xMlg3Pjl7IN88US=>	MWHTRW5ITVJ?
LOXIMVI	NWXH[Gw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnLfWhiUUN3ME2xMlg6PDJ5IN88US=>	MWrTRW5ITVJ?
BPH-1	NYL1TFlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH4TWM2OD1zLki5OVkyKM7:TR?=	NXLmUnJzW0GQR1XS
A375	NULnTnFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XFXGlEPTB;MT64PVcyPCEQvF2=	NXrPZ29pW0GQR1XS
LCLC-97TM1	M3fk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwOUKyOVYh\|ryP	NXL3fJdoW0GQR1XS
RXF393	M3L3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFu5dXRKSzVyPUGuPVc5QDdizszN	NEK1SWdUSU6JRWK=
HCC70	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\3SHdKUUN3ME2yMlAzPDJ4IN88US=>	NGfQNnFUSU6JRWK=
EM-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TOTmlEPTB;Mj6wO\|E6QCEQvF2=	NHzncnRUSU6JRWK=
MZ2-MEL	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjKTWM2OD1{LkGxNVI4KM7:TR?=	NITXbYpUSU6JRWK=
HN	M4rEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjnS3B{UUN3ME2yMlE3Ojd6IN88US=>	Mn74V2FPT0WU
A2058	MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLufGNKSzVyPUKuNVkzPzlizszN	NFroNlRUSU6JRWK=
NB7	NWHGbWp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTJwM{SwPFYh\|ryP	MYLTRW5ITVJ?
DOK	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i0W2lEPTB;Mj6zOVc4OyEQvF2=	MUDTRW5ITVJ?
CAL-27	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH6N3hKSzVyPUKuN\|kzOzZizszN	MWXTRW5ITVJ?
BB65-RCC	M4HXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jDd2lEPTB;Mj60NFY4PCEQvF2=	MlPEV2FPT0WU
RD	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofvTWM2OD1{LkS0O\|I{KM7:TR?=	M{HxN3NCVkeHUh?=
KNS-62	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoL2TWM2OD1{LkWxNVY1KM7:TR?=	MUnTRW5ITVJ?
EW-13	M4f1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfMTWM2OD1{LkW2N\|M6KM7:TR?=	NEixW3VUSU6JRWK=
DB	NXziUoRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHoepFKSzVyPUKuOVg4QDhizszN	M1zRXXNCVkeHUh?=
HCC2218	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\ESJZoUUN3ME2yMlY1Pzd6IN88US=>	NHXRRplUSU6JRWK=
L-363	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnJTWM2OD1{Lke0N\|ch\|ryP	NFnGeJBUSU6JRWK=
CHL-1	MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTJwOEC3PFUh\|ryP	NWr6ZlBkW0GQR1XS
BFTC-905	M3W2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnuyTWM2OD1{LkiyOVMh\|ryP	NV72[49JW0GQR1XS
HCE-T	NFnXeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;mXFc5UUN3ME2yMlg{OjZ2IN88US=>	MUXTRW5ITVJ?
COLO-792	NVy0NWpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\XT5BwUUN3ME2yMlg1ODJ5IN88US=>	MlfzV2FPT0WU
LB2241-RCC	NFryfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PRXGlEPTB;Mj64OVg6OyEQvF2=	NHHISlFUSU6JRWK=
CAL-39	NFmyeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTJwOEm5PVkh\|ryP	M4LseXNCVkeHUh?=
T-24	NXm1TFgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTJwOUGxNVIh\|ryP	Mmr0V2FPT0WU
NCI-H727	NXrveGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJwOUG3PVYh\|ryP	M1z4VnNCVkeHUh?=
Ca9-22	M3rpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnRTWM2OD1{Lkm3NlU2KM7:TR?=	MUHTRW5ITVJ?
MIA-PaCa-2	NXrVVZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfKU4pKSzVyPUOuNFA4QDFizszN	Mnq1V2FPT0WU
HT-1080	NF\vN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\DbGlEPTB;Mz6wNVk6PyEQvF2=	MlSxV2FPT0WU
D-423MG	M2GxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvxbIlqUUN3ME2zMlA4PzV\|IN88US=>	MkDaV2FPT0WU
LAMA-84	NYTMT2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmK5TWM2OD1\|LkGzOVgh\|ryP	Mlr4V2FPT0WU
SW780	M3zYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LBe2lEPTB;Mz6xOFIzQSEQvF2=	M4PJUHNCVkeHUh?=
KU-19-19	MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljtTWM2OD1\|LkG3NFM1KM7:TR?=	Mlr3V2FPT0WU
COLO-741	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPue3RKSzVyPUOuNVg3PzNizszN	M3S2e3NCVkeHUh?=
HSC-3	NWm2OXhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NESwdlVKSzVyPUOuNlMyPTFizszN	Mm\5V2FPT0WU
SN12C	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4W2ZmlEPTB;Mz6yOFcxOSEQvF2=	NFPUVIZUSU6JRWK=
786-0	M1jmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M330[2lEPTB;Mz6yO\|I1OyEQvF2=	NFzwXlRUSU6JRWK=
GAK	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[yNnpKSzVyPUOuN\|I2PjFizszN	M365S3NCVkeHUh?=
PANC-03-27	NVSxVoZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnaeIRFUUN3ME2zMlM2ODR3IN88US=>	M3vZW3NCVkeHUh?=
CTB-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTNwNEewOFch\|ryP	MkD3V2FPT0WU
A427	NU\qZ3NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LIPWlEPTB;Mz61PVU2PiEQvF2=	NHv6TVBUSU6JRWK=
EGI-1	NYnYXnJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTNwNkC1PFMh\|ryP	NY[3XIpsW0GQR1XS
U-2-OS	M2\Z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTNwNkeyOVYh\|ryP	M3HJ[XNCVkeHUh?=
NCI-SNU-5	M2TZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTNwNke3N{DPxE1?	NXS4cXdyW0GQR1XS
SK-LU-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moj3TWM2OD1\|Lk[4O\|k5KM7:TR?=	NWrQZXpLW0GQR1XS
697	M1\OWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXSze\|R6UUN3ME2zMlY6PjB\|IN88US=>	NXvsTIpEW0GQR1XS
HPAF-II	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnCb4hKSzVyPUOuO\|U1QSEQvF2=	NIPwc4ZUSU6JRWK=
NCI-H2087	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfCTWM2OD1\|Lki0OlczKM7:TR?=	M3\qOHNCVkeHUh?=
SK-MEL-3	NWnrV2tCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fufGlEPTB;Mz64OVE2PCEQvF2=	MYnTRW5ITVJ?
CGTH-W-1	Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnuPYtJUUN3ME2zMlg2PzJ3IN88US=>	NIHDXpBUSU6JRWK=
8505C	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\OZWlEPTB;Mz65NFA4QCEQvF2=	M{\v[XNCVkeHUh?=
GAMG	M{fOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDt[4hKSzVyPUSuNFI{PzdizszN	NFzK[GxUSU6JRWK=
SW626	Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHxTWM2OD12LkC0OFgh\|ryP	NE\5SJhUSU6JRWK=
CAL-62	M4[xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTRwMEe0N{DPxE1?	M2TGTnNCVkeHUh?=
MHH-PREB-1	MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTRwMUKxNVEh\|ryP	NXfTXnFKW0GQR1XS
RPMI-7951	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TyWWlEPTB;ND6yOVU5QSEQvF2=	MWDTRW5ITVJ?
HOP-92	Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT3WYpKSzVyPUSuNlU3PyEQvF2=	MXPTRW5ITVJ?
MDA-MB-231	NGGxNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHkU4ZKSzVyPUSuNlkzOjNizszN	NEXKenZUSU6JRWK=
LAN-6	M2TsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTRwM{G2N\|ch\|ryP	NWH1SllZW0GQR1XS
ALL-PO	NI\3e4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nEPGlEPTB;ND6zOlE2PiEQvF2=	MXjTRW5ITVJ?
HH	NG[xXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDyPHhtUUN3ME20MlQyPTl5IN88US=>	NWXsVZF1W0GQR1XS
IGROV-1	NFnPU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnBc2VPUUN3ME20MlQ2OTdzIN88US=>	Mo\WV2FPT0WU
NCI-H358	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTRwNEWzPFUh\|ryP	M4XIU3NCVkeHUh?=
NB5	M2jmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PpOmlEPTB;ND62NFM3QSEQvF2=	M37xe3NCVkeHUh?=
NCI-H747	M{HMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTRwNki4NFch\|ryP	NGHBUXJUSU6JRWK=
NH-12	NWTsTFBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvFVXZ6UUN3ME20MlcyPjJ3IN88US=>	NH[yRY5USU6JRWK=
LB1047-RCC	M1nkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLZOphlUUN3ME20Mlc{QDF3IN88US=>	NV72dJhTW0GQR1XS
EFO-27	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXWcGtKSzVyPUSuO\|g3PjdizszN	NXXV[pNRW0GQR1XS
EPLC-272H	NXzZemVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H6SmlEPTB;ND65PVY3QSEQvF2=	M{DIbXNCVkeHUh?=
CAL-54	M{TjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rKcmlEPTB;NT6wNlY6PSEQvF2=	M{j0fHNCVkeHUh?=
H4	M1vUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPLSnNbUUN3ME21MlA1OjV3IN88US=>	NXHY[2xFW0GQR1XS
MOLT-13	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmX5TWM2OD13LkC2O\|c3KM7:TR?=	NFrEcplUSU6JRWK=
CAL-33	M{TSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjxPJFbUUN3ME21MlEzOzF5IN88US=>	M{TleHNCVkeHUh?=
23132-87	M3;6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorXTWM2OD13LkG2PFczKM7:TR?=	MmKwV2FPT0WU
UM-UC-3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr2OnRKSzVyPUWuNVgxPDdizszN	NWTVXVlXW0GQR1XS
HuH-7	M2DTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XXRWlEPTB;NT6yO\|E1PyEQvF2=	NHzLUHdUSU6JRWK=
BCPAP	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTVwM{K5Olkh\|ryP	NYT1PVByW0GQR1XS
AsPC-1	NITuPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\NcWlEPTB;NT6zOlc3OyEQvF2=	M3G3NXNCVkeHUh?=
NCI-H1155	NYSxUpd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDKTWM2OD13LkSwNFUyKM7:TR?=	M2\SUXNCVkeHUh?=
GT3TKB	M2DhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTVwNE[1PVgh\|ryP	NF7kZ5FUSU6JRWK=
HCC2998	M1u5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XtNWlEPTB;NT60PVExQSEQvF2=	NFfHW5FUSU6JRWK=
NUGC-3	NGPQc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3OUFI3UUN3ME21MlQ6OzB{IN88US=>	NIm5WWZUSU6JRWK=
Hs-578-T	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[xTWM2OD13LkWzO\|k1KM7:TR?=	MUHTRW5ITVJ?
FADU	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTVwNUW3NlYh\|ryP	NIniSFJUSU6JRWK=
NBsusSR	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTVwNUexOVUh\|ryP	NX\3R3d6W0GQR1XS
ME-180	NELjXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfsZm1KSzVyPUWuOVgxQTJizszN	NGH4d4dUSU6JRWK=
SW1710	NYq2SnRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rFVWlEPTB;NT62NVY2PCEQvF2=	M1[2dXNCVkeHUh?=
HuP-T3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTVwNkKwNlkh\|ryP	MmftV2FPT0WU
HOS	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTVwNkK5NlMh\|ryP	MUPTRW5ITVJ?
PA-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVr6WIlPUUN3ME21MlY1OjZ3IN88US=>	NF\lO2pUSU6JRWK=
LU-99A	Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTVwNk[0OVEh\|ryP	NWTpRWtTW0GQR1XS
RS4-11	M4HIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHoTWM2OD13Lk[2O\|c2KM7:TR?=	M1L0TXNCVkeHUh?=
TE-8	NF7KV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWD5R5BZUUN3ME21MlY5PTN5IN88US=>	NYS3XnFxW0GQR1XS
RERF-LC-MS	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnGSYVKSzVyPUWuOlg5ODNizszN	NVjsUlJ5W0GQR1XS
MEL-JUSO	M4fMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTVwN{O3PEDPxE1?	M3PTfXNCVkeHUh?=
SK-MES-1	NG[0OY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[1SYdKSzVyPUWuPFM2OjhizszN	MV7TRW5ITVJ?
D-263MG	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTVwOEizOVEh\|ryP	NY\vNZdvW0GQR1XS
NB10	NI\0eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHuTWM2OD13Lki5OFYh\|ryP	Ml3rV2FPT0WU
SK-HEP-1	M1fXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13r[mlEPTB;NT65N\|Q4OSEQvF2=	M4DMRXNCVkeHUh?=
HT-29	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGO0VmtKSzVyPUWuPVgyOThizszN	NVfUNIxmW0GQR1XS
KYSE-140	M4X3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTXVHNqUUN3ME22MlAzOTh{IN88US=>	MV\TRW5ITVJ?
NCI-H1666	M1nBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXKyUpBWUUN3ME22MlA5PDZzIN88US=>	Mlu2V2FPT0WU
NCI-H1304	M2TNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTZwMUm5OEDPxE1?	MX3TRW5ITVJ?
RPMI-8866	NGjodmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHWRnFKSzVyPU[uNlE{OTNizszN	M1LrSXNCVkeHUh?=
MV-4-11	MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mny1TWM2OD14LkKzNVk6KM7:TR?=	NUTySFFoW0GQR1XS
A431	M{XsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{H1RmlEPTB;Nj6yOFI6PiEQvF2=	MXrTRW5ITVJ?
PANC-10-05	M4nCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nrPGlEPTB;Nj6yPFM3OyEQvF2=	MUjTRW5ITVJ?
TK10	MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWr2e5dlUUN3ME22MlMzPjB2IN88US=>	NWq4TnB2W0GQR1XS
NCI-H1975	NX30VYVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTZwNEeyNVUh\|ryP	MUfTRW5ITVJ?
A172	MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTZwNEmxO\|Yh\|ryP	NHn1fZBUSU6JRWK=
D-566MG	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7kNXJKSzVyPU[uOVQ{ODNizszN	NVLvUZBxW0GQR1XS
NCI-H2122	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jkcWlEPTB;Nj62NVUzQCEQvF2=	NHXhem1USU6JRWK=
COR-L105	MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTZwNkWyO\|Uh\|ryP	NUXKR4psW0GQR1XS
AN3-CA	NUTIZmhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEGz[GFKSzVyPU[uOlg3PDFizszN	NFizSIxUSU6JRWK=
Calu-6	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7xTJM2UUN3ME22Mlc6Pjl6IN88US=>	MYHTRW5ITVJ?
HCT-116	NH7KUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XEcGlEPTB;Nj64NVI3PCEQvF2=	MojoV2FPT0WU
MHH-NB-11	NH[0WnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLvTWM2OD14Lki1NFAzKM7:TR?=	NGfjPY1USU6JRWK=
MFE-280	NF64cXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTZwOEW5PFMh\|ryP	MYPTRW5ITVJ?
SW1088	M1vuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPqTWM2OD14LkmxPVE{KM7:TR?=	NX71WZVEW0GQR1XS
SW48	NXX2THV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTZwOUS1NUDPxE1?	NHfTPGJUSU6JRWK=
HuCCT1	M33rfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHrSHlKSzVyPUeuNFExOzdizszN	MXPTRW5ITVJ?
ACHN	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\CTWM2OD15LkCyPVQ{KM7:TR?=	NGXvXlVUSU6JRWK=
8305C	M4flUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETjRVRKSzVyPUeuNFk6QTVizszN	NVzwPHJrW0GQR1XS
DoTc2-4510	M2jkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XxN2lEPTB;Nz6xNlE2KM7:TR?=	M3n2T3NCVkeHUh?=
COR-L23	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;STWM2OD15LkK0OFIh\|ryP	MmHnV2FPT0WU
SK-MEL-30	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHaTWM2OD15LkK1NFg{KM7:TR?=	MWPTRW5ITVJ?
BE-13	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3oTZFvUUN3ME23MlM{QDN2IN88US=>	NID0TGdUSU6JRWK=
GR-ST	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTdwNECxO\|Qh\|ryP	NHTZSmpUSU6JRWK=
LU-135	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PE[WlEPTB;Nz61OVk{QSEQvF2=	NEPORWFUSU6JRWK=
U-266	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTdwNU[yPFYh\|ryP	M1\weHNCVkeHUh?=
NCI-H1355	MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVuwNFg5UUN3ME23MlU5PjN3IN88US=>	M3yzcnNCVkeHUh?=
NB14	NUP4NXJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrxRpBKSzVyPUeuOlY3PDJizszN	MWTTRW5ITVJ?
SCC-25	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTdwN{C5JO69VQ>?	NIe2bmNUSU6JRWK=
COLO-678	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTdwN{GwO\|Yh\|ryP	M1fKcXNCVkeHUh?=
TGBC1TKB	M{LmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jtVWlEPTB;Nz64PVM6QCEQvF2=	NWLmTYhbW0GQR1XS
IST-MEL1	M{S4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRThwMEC0NFYh\|ryP	Mm\6V2FPT0WU
ECC10	NHnsTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfCTWM2OD16LkCzN\|k2KM7:TR?=	NXjmWVFYW0GQR1XS
EW-16	MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmW5TWM2OD16LkC4OFQ2KM7:TR?=	MXHTRW5ITVJ?
DOHH-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7BTWM2OD16LkKwNFk2KM7:TR?=	NWTB[2REW0GQR1XS
NCI-H1581	M4HWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPxTnpKSzVyPUiuNlY{OjNizszN	MULTRW5ITVJ?
TE-5	M3PuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljBTWM2OD16LkSyOFI6KM7:TR?=	MX;TRW5ITVJ?
CAKI-1	M1vSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fIVmlEPTB;OD61O\|IzOiEQvF2=	NEHDfVlUSU6JRWK=
A673	M3nlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRThwNkOyNFIh\|ryP	MVrTRW5ITVJ?
CAL-12T	NX3MUZIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHPVGJKSzVyPUiuOlU4PTNizszN	M2ruSnNCVkeHUh?=
DBTRG-05MG	NHW3VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRThwN{S4OVkh\|ryP	MlvwV2FPT0WU
SK-N-FI	NI\qcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HlNGlEPTB;OD64NVM4QSEQvF2=	NFjGbINUSU6JRWK=
K-562	M{jVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRThwOEO5OVch\|ryP	MWHTRW5ITVJ?
SBC-1	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXFbXpKSzVyPUiuPFY3PDVizszN	MoLRV2FPT0WU
ES4	NY\jT5BET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3rbpJKSzVyPUiuPFY5QDRizszN	MULTRW5ITVJ?
MS-1	NED4ZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjTUFFVUUN3ME24Mlg4PTF5IN88US=>	NHjOdZVUSU6JRWK=
RKO	NFHkOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRThwOEmwOVch\|ryP	M3KzUnNCVkeHUh?=
NCI-H1693	M{TOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PQT2lEPTB;OD65NlE4KM7:TR?=	NVfaTHc4W0GQR1XS
SW954	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjmRXpFUUN3ME24Mlk3QTd6IN88US=>	NVHtdldiW0GQR1XS
SK-UT-1	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETCWYxKSzVyPUiuPVc3QDNizszN	MUHTRW5ITVJ?
T98G	NIXzWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP0XHZ7UUN3ME24Mlk6QDR4IN88US=>	M4[yOXNCVkeHUh?=
NCI-H2126	MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGe1R25KSzVyPUmuNFA5OjZizszN	MnnvV2FPT0WU
TE-12	NUW5bXR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEna[3NKSzVyPUmuNFM{PjdizszN	MlrwV2FPT0WU
DK-MG	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTlwMkGxPVEh\|ryP	NFn5O2NUSU6JRWK=
MEG-01	NFzJfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH:0[m5KSzVyPUmuNlQ6OzFizszN	NHzoPYhUSU6JRWK=
HCC1937	M3SxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnJXHVbUUN3ME25MlI6ODlzIN88US=>	M4XTT3NCVkeHUh?=
MKN45	NFm1UZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;ZOmRKSzVyPUmuOFUxPjVizszN	M1rWOHNCVkeHUh?=
NCI-H1792	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLTNHBKSzVyPUmuOFUzOTlizszN	NHnYTYlUSU6JRWK=
SW1417	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4r2UWlEPTB;OT61Olg{PyEQvF2=	MX;TRW5ITVJ?
639-V	M1X4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTlwNkSzPFgh\|ryP	M1PES3NCVkeHUh?=
P30-OHK	NV3VfmlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\H[2lEPTB;OT62OVMyPiEQvF2=	NUex[3ZwW0GQR1XS
YKG-1	NYfqOGd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7tVGpyUUN3ME25Mlc2ODN\|IN88US=>	NYL1bFdFW0GQR1XS
KGN	NXv5eoVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HZNGlEPTB;OT64N\|c6PSEQvF2=	Mo[3V2FPT0WU
MSTO-211H	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTlwOUW1Nlkh\|ryP	NEDneYZUSU6JRWK=
NCI-H1573	NUHUN2dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrRWFBKSzVyPUGwMlE2PzRizszN	M2CxUnNCVkeHUh?=
NCI-H720	NFq0ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTFyLkG5PFkh\|ryP	M4GwcXNCVkeHUh?=
KARPAS-45	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnXUHRVUUN3ME2xNE4zPzl3IN88US=>	NVm5WYhzW0GQR1XS
MDA-MB-175-VII	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjNWWo6UUN3ME2xNE41QCEQvF2=	NXm0eZo4W0GQR1XS
SK-NEP-1	NEW5N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTFyLkS5PFEh\|ryP	MkDJV2FPT0WU
MKN28	MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzOfoVKSzVyPUGwMlUyQCEQvF2=	NYTHXm5mW0GQR1XS
KYSE-520	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkC3TWM2OD1zMD61NkDPxE1?	MofxV2FPT0WU
KE-37	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYS2PGF[UUN3ME2xNE42Ojd{IN88US=>	MkTkV2FPT0WU
VA-ES-BJ	M2TWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonPTWM2OD1zMD61Olch\|ryP	NIrXfG5USU6JRWK=
CCRF-CEM	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTFyLkW2PFQh\|ryP	NEf3[W1USU6JRWK=
GMS-10	NU\kVXhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PQfGlEPTB;MUCuOlA6PCEQvF2=	NVjsRlVlW0GQR1XS
NCI-H1623	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnryTWM2OD1zMD62N\|c6KM7:TR?=	NFX6[IxUSU6JRWK=
NEC8	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHFTWM2OD1zMD63O\|c{KM7:TR?=	M3XSRnNCVkeHUh?=
MOLT-16	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGGxT2xKSzVyPUGwMlgyOTNizszN	MX;TRW5ITVJ?
DJM-1	M3Lm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTFzLkCzO\|kh\|ryP	M1jDcXNCVkeHUh?=
U251	Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjVPHZtUUN3ME2xNU4xPDJizszN	MmjMV2FPT0WU
SBC-5	NXjoU4VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTFzLkG0Olch\|ryP	MUDTRW5ITVJ?
SW756	NGficldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DjTWlEPTB;MUGuNlE2PCEQvF2=	MmjtV2FPT0WU
KS-1	NVq5XVdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnESndKSzVyPUGxMlI3OTlizszN	M2LmenNCVkeHUh?=
SF295	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlG2TWM2OD1zMT6zNVA1KM7:TR?=	NGr6TGFUSU6JRWK=
YH-13	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTPZo1KSzVyPUGxMlMzPjdizszN	MmPCV2FPT0WU
SW837	NX62PZZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\STWM2OD1zMT6zOVA3KM7:TR?=	NIjDbJVUSU6JRWK=
KYSE-450	NVnT[\|RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknFTWM2OD1zMT60NFU4KM7:TR?=	NUPWfWszW0GQR1XS
KYSE-180	NEfPdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTFzLkS4NkDPxE1?	M4THdHNCVkeHUh?=
S-117	NGnDdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILT[lFKSzVyPUGxMlQ5QTZizszN	M2jVXXNCVkeHUh?=
KOSC-2	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;PTWM2OD1zMT62NlIzKM7:TR?=	NFjtPYNUSU6JRWK=
KYSE-270	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFzLki3OFUh\|ryP	MWXTRW5ITVJ?
D-336MG	NHfUeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTFzLkmwO\|Uh\|ryP	NFOyXYxUSU6JRWK=
KALS-1	MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7LNohlUUN3ME2xNk4xODF4IN88US=>	MmrnV2FPT0WU
LB373-MEL-D	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XsbmlEPTB;MUKuNFU{OyEQvF2=	M2XpcXNCVkeHUh?=
HLE	NEjVUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nB[GlEPTB;MUKuNFU5PSEQvF2=	NWL6b4R[W0GQR1XS
SJSA-1	NUi4PZNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTF{LkC3N\|Uh\|ryP	MkLGV2FPT0WU
SW1990	NUXOfINMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M370XmlEPTB;MUKuNFkyOSEQvF2=	MU\TRW5ITVJ?
NOS-1	M2HJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTF{LkGzOVIh\|ryP	NWDE[45RW0GQR1XS
GI-ME-N	MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q4[WlEPTB;MUKuNlE3OyEQvF2=	MkHvV2FPT0WU
NCI-H1703	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTF{LkK2NVYh\|ryP	MUPTRW5ITVJ?
ES7	NGXXXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[2TWM2OD1zMj6yO\|I1KM7:TR?=	MUPTRW5ITVJ?
KYSE-510	M{TDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPENJVQUUN3ME2xNk42ODd7IN88US=>	NUDJUFc3W0GQR1XS
BHY	NG\nTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTF{LkWzNFch\|ryP	MVHTRW5ITVJ?
TCCSUP	NYPWZZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvxTWM2OD1zMj61O\|U4KM7:TR?=	MY\TRW5ITVJ?
HSC-2	NGL3bY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfSZWVvUUN3ME2xNk42QTl4IN88US=>	NVrze\|ZoW0GQR1XS
BEN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3W1RmlEPTB;MUKuOlE1OyEQvF2=	MX;TRW5ITVJ?
769-P	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXaV25KSzVyPUGyMlc6OjRizszN	MWXTRW5ITVJ?
HT	M2HVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTF{LkizOFYh\|ryP	M3PIPXNCVkeHUh?=
LXF-289	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLnR29KSzVyPUGyMlk2OzFizszN	NEjOdo5USU6JRWK=
OVCAR-3	M3j5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jaW2lEPTB;MUKuPVU3PyEQvF2=	Mo\JV2FPT0WU
ATN-1	M{exSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTsTWM2OD1zMz6wNVg1KM7:TR?=	M3;SUnNCVkeHUh?=
8-MG-BA	NVXZNHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjTTWM2OD1zMz6wOFU2KM7:TR?=	NI\mc2NUSU6JRWK=
SW13	M4XjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXX[oNKSzVyPUGzMlEyPjVizszN	MX;TRW5ITVJ?
NCI-H1092	NV7XNJpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmm0TWM2OD1zMz6xOlIh\|ryP	NWjpSWpPW0GQR1XS
OAW-42	M{i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2juOWlEPTB;MUOuNVk{PyEQvF2=	MWLTRW5ITVJ?
NCI-H2452	NHzYTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml75TWM2OD1zMz6yNVc2KM7:TR?=	Ml[5V2FPT0WU
CAPAN-1	M16z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLvTWM2OD1zMz61OVE1KM7:TR?=	M1PE[3NCVkeHUh?=
NCI-H2009	M32wcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLXTWM2OD1zMz61PVE6KM7:TR?=	NUDaV3VnW0GQR1XS
SF268	M132fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF36Om1KSzVyPUGzMlY{OjZizszN	MVTTRW5ITVJ?
GCIY	MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITCb4dKSzVyPUGzMlY6OjdizszN	NVvOU3NyW0GQR1XS
OS-RC-2	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTyeFJKSzVyPUGzMlk2ODFizszN	MW\TRW5ITVJ?
GCT	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm[wTWM2OD1zMz65Olk4KM7:TR?=	NHr0[2dUSU6JRWK=
NB17	M3[xRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT0fJdnUUN3ME2xOE4xQDVizszN	MknsV2FPT0WU
NCI-H2030	M3uzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGP6NWhKSzVyPUG0MlE1PjVizszN	NX\ZR49pW0GQR1XS
HC-1	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7pR3dSUUN3ME2xOE4zODh5IN88US=>	MXLTRW5ITVJ?
QIMR-WIL	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfBTWM2OD1zND6zOFEzKM7:TR?=	MWDTRW5ITVJ?
Capan-2	MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\jW5BKSzVyPUG0MlM4OTRizszN	NFzieHFUSU6JRWK=
BALL-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4P1WGlEPTB;MUSuOFY3PSEQvF2=	NVLtUmZqW0GQR1XS
LS-1034	MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPZRmxRUUN3ME2xOE43OTV{IN88US=>	MVfTRW5ITVJ?
U-118-MG	M4\qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rDe2lEPTB;MUSuOlMyKM7:TR?=	NXTvNYNVW0GQR1XS
NCI-H630	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfFTWM2OD1zND62OVY5KM7:TR?=	MVrTRW5ITVJ?
OVCAR-8	NXnzT2trT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvObGlKSzVyPUG0MlczODFizszN	NWfkS4tzW0GQR1XS
NCI-H2347	NVruSHpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkmwTWM2OD1zND64NlMh\|ryP	NG\MbmRUSU6JRWK=
BT-549	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDIOlVnUUN3ME2xOE45Ojh2IN88US=>	NWHQToRCW0GQR1XS
LB831-BLC	M2DuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTF2Lki5N\|Qh\|ryP	NXXGUlN[W0GQR1XS
NCI-H661	M3\QR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT5WlhKSzVyPUG0Mlk2QSEQvF2=	MnP1V2FPT0WU
MKN7	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\lXW5KSzVyPUG1MlAxQTNizszN	NWDOR4R1W0GQR1XS
U-87-MG	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mor1TWM2OD1zNT6wPFk4KM7:TR?=	NHrH[pBUSU6JRWK=
OVCAR-4	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXoTJFKSzVyPUG1MlE1OjRizszN	M4fTNnNCVkeHUh?=
OE33	NX;LbGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTUTWM2OD1zNT6xO\|EyKM7:TR?=	MYfTRW5ITVJ?
EC-GI-10	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVS4PI85UUN3ME2xOU4zOzV5IN88US=>	MlLQV2FPT0WU
AM-38	MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{W0dmlEPTB;MUWuNlcyPyEQvF2=	M1S1WnNCVkeHUh?=
NCI-H1563	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjTb\|NKSzVyPUG1MlM1QSEQvF2=	MWXTRW5ITVJ?
SCC-4	M37XTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojZTWM2OD1zNT60NVA{KM7:TR?=	NWXScZdzW0GQR1XS
Detroit562	NHzMVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2P5VWlEPTB;MUWuOFU1PyEQvF2=	MlrJV2FPT0WU
PC-14	NFSyZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fIOmlEPTB;MUWuOFg3PiEQvF2=	NVjzXXF6W0GQR1XS
ES3	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFOyZ\|ZKSzVyPUG1MlU{PiEQvF2=	NHLIOppUSU6JRWK=
OCI-AML2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLhZWdxUUN3ME2xOU44PjF2IN88US=>	MkjtV2FPT0WU
LU-134-A	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf0TWM2OD1zNT65NFE5KM7:TR?=	NF;HRXVUSU6JRWK=
SAS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHXTWM2OD1zNT65N\|c{KM7:TR?=	MWnTRW5ITVJ?
TGBC11TKB	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofaTWM2OD1zNT65OFE1KM7:TR?=	MkK0V2FPT0WU
HOP-62	NX72ZVhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;BT4ZUUUN3ME2xOU46PTl5IN88US=>	MUDTRW5ITVJ?
G-401	NVXxT2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXzUJNKSzVyPUG1Mlk3PDlizszN	NV\oTFhUW0GQR1XS
NCI-H28	NUm4WnNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H2PWlEPTB;MU[uNFg2PiEQvF2=	NGHaZnhUSU6JRWK=
A204	M2PWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrFVWhKSzVyPUG2MlIxODZizszN	NVexemJ6W0GQR1XS
NCI-H1299	M3XpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlL6TWM2OD1zNj6yNlkyKM7:TR?=	Ml[zV2FPT0WU
VMRC-RCZ	NYXNOmRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HmUWlEPTB;MU[uNlU6OiEQvF2=	NF3BS3NUSU6JRWK=
BxPC-3	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3nTWM2OD1zNj6yPFU3KM7:TR?=	MUnTRW5ITVJ?
NCI-H2228	NXvwPXozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTF4LkWxOVgh\|ryP	MV\TRW5ITVJ?
NCI-H23	NYXH[mhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLVTWM2OD1zNj62NFc5KM7:TR?=	MXPTRW5ITVJ?
NKM-1	NETsc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnac4tKSzVyPUG3MlAyQDlizszN	NFXmVXRUSU6JRWK=
KYSE-70	NILrV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET5NXFKSzVyPUG3MlI5QSEQvF2=	M3zPZnNCVkeHUh?=
BB49-HNC	Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXVTWM2OD1zNz61Olg3KM7:TR?=	MkHXV2FPT0WU
SCC-15	M4nve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoK3TWM2OD1zNz64OFc{KM7:TR?=	MmnzV2FPT0WU
D-247MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XGNGlEPTB;MUeuPVI1PyEQvF2=	NYHNeZg4W0GQR1XS
BB30-HNC	M4HwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvtTWM2OD1zOD6wN\|E5KM7:TR?=	NIr5dIJUSU6JRWK=
CAL-85-1	M1XaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLvTWM2OD1zOD6xPFA6KM7:TR?=	NHfGUmJUSU6JRWK=
HT-3	NGLLc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HYc2lEPTB;MUiuN\|k4PyEQvF2=	M17pW3NCVkeHUh?=
KYSE-410	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfwRWJKSzVyPUG4MlQ2PzdizszN	MWDTRW5ITVJ?
SW982	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LLV2lEPTB;MUiuOVY1QSEQvF2=	NFjmV4RUSU6JRWK=
SW962	M1u3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3LV2Q6UUN3ME2xPE42PzB{IN88US=>	MkHVV2FPT0WU
Ramos-2G6-4C10	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfJbXgzUUN3ME2xPE42QTJ5IN88US=>	MV;TRW5ITVJ?
OC-314	M3rBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Xud2lEPTB;MUiuO\|M5PCEQvF2=	NIrFSGVUSU6JRWK=
LS-123	NY\ScI12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfp[pZKSzVyPUG4Mlc6ODFizszN	NWXHUmNwW0GQR1XS
D-502MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fERmlEPTB;MUiuPFE{QSEQvF2=	MmXFV2FPT0WU
RO82-W-1	NUT5O\|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTF6LkiyPFgh\|ryP	MkDEV2FPT0WU
HuO9	NWOxOVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDJ[lR7UUN3ME2xPU4yOzd7IN88US=>	NV7YS\|NwW0GQR1XS
ETK-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzRfYJKSzVyPUG5MlE5OjdizszN	M{SyW3NCVkeHUh?=
SNU-387	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;tdmlEPTB;MUmuNVg5QSEQvF2=	MlmyV2FPT0WU
SW1573	NUC0U\|dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXaTWM2OD1zOT6xPVY6KM7:TR?=	M1TkUHNCVkeHUh?=
NTERA-S-cl-D1	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVqxbGFsUUN3ME2xPU4zODB5IN88US=>	MnXVV2FPT0WU
SF126	NH;uc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfDbGt3UUN3ME2xPU4{PTB{IN88US=>	M1XoXHNCVkeHUh?=
Calu-3	NUflO3FrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLyTWM2OD1zOT60NlM4KM7:TR?=	MX;TRW5ITVJ?
NCI-H1048	NUe4OIJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfKTWM2OD1{MD6zNlY3KM7:TR?=	MVHTRW5ITVJ?
NCI-H226	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX30OFV3UUN3ME2yNE41Ozl7IN88US=>	NWWzSW1lW0GQR1XS
FTC-133	M4rjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rqbGlEPTB;MkCuOFcxOyEQvF2=	NXnH[5F{W0GQR1XS
SF539	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJyLkWxO\|Ih\|ryP	MnTuV2FPT0WU
TE-6	NFnzRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHOem9KSzVyPUKwMlgxPjdizszN	MWDTRW5ITVJ?
UMC-11	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJyLkmxOlQh\|ryP	Mn3hV2FPT0WU
Becker	NFrNT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIG2S3VKSzVyPUKxMlEyOThizszN	M1rBRnNCVkeHUh?=
KP-4	NHTJSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTJzLkGxPVYh\|ryP	NYjJ[XZqW0GQR1XS
ChaGo-K-1	NFjuNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r0N2lEPTB;MkGuN\|YzPyEQvF2=	MVLTRW5ITVJ?
CFPAC-1	NUH2eWh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjuTWM2OD1{MT6zPFU5KM7:TR?=	NHn4Wm1USU6JRWK=
A498	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4f5dGlEPTB;MkGuOVMyOiEQvF2=	M3nOSXNCVkeHUh?=
NCI-H1755	NWHlPJpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfkTWM2OD1{MT62O\|QyKM7:TR?=	NGK2TZVUSU6JRWK=
TI-73	NYfZZnI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlP5TWM2OD1{Mj6zNlgh\|ryP	M3HJSnNCVkeHUh?=
NCI-H441	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTJ{LkW2PFkh\|ryP	NXjyXWVYW0GQR1XS
CaR-1	NGKyWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTJ\|LkCyNVMh\|ryP	MlHKV2FPT0WU
HCC1806	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHRSW1rUUN3ME2yN{4xPTh\|IN88US=>	NV;zTYhDW0GQR1XS
SNU-449	M3H6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnYTWM2OD1{Mz6zNlkh\|ryP	MkfCV2FPT0WU
EKVX	NYTEXVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{n1WWlEPTB;MkOuN\|kxQSEQvF2=	NVXFcnJbW0GQR1XS
DMS-114	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXUTWM2OD1{Mz61O\|Y2KM7:TR?=	NFfhOmlUSU6JRWK=
A704	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJ\|Lk[xNFMh\|ryP	MYnTRW5ITVJ?
LC-2-ad	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTJ\|Lk[xOFch\|ryP	M2HlTnNCVkeHUh?=
VM-CUB-1	NEjQRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTJ\|LkezOFEh\|ryP	MUnTRW5ITVJ?
PC-3	NV:5S3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4izZmlEPTB;MkSuNFUzPiEQvF2=	MlzXV2FPT0WU
HEL	NGnyXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q5d2lEPTB;MkSuNFg3PSEQvF2=	M1\l[3NCVkeHUh?=
ABC-1	NYfVR3hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O0UGlEPTB;MkSuNlczQSEQvF2=	NXzMfm82W0GQR1XS
COLO-680N	M4\mTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvZSVFlUUN3ME2yOE41PzZ2IN88US=>	NXjZVW5DW0GQR1XS
MZ1-PC	Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[3dmlEPTB;MkSuOlg4KM7:TR?=	MnzCV2FPT0WU
NCI-H69	M{DxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTJ2LkezOVQh\|ryP	MlHCV2FPT0WU
TE-1	NHntXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHJZollUUN3ME2yOU4xPDl7IN88US=>	MYjTRW5ITVJ?
EW-3	NUTaeZlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoWzTWM2OD1{NT6xNVMh\|ryP	MYPTRW5ITVJ?
PANC-08-13	NGnEVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nDO2lEPTB;MkWuPFExOyEQvF2=	MYTTRW5ITVJ?
NMC-G1	M2HKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{naWWlEPTB;Mk[uNFA5QCEQvF2=	NWXhdlh4W0GQR1XS
BT-20	NHrETplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjIbnZKSzVyPUK2MlQ2PDNizszN	M2HsUnNCVkeHUh?=
TGBC24TKB	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDlUJNKSzVyPUK2Mlc{OzFizszN	M3\SSHNCVkeHUh?=
TE-11	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;yeXRKSzVyPUK2Mlk5QTVizszN	MWjTRW5ITVJ?
ESS-1	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTPTWM2OD1{Nz6zNlE3KM7:TR?=	NVrrfm9vW0GQR1XS
JVM-3	M2P5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnVWnhtUUN3ME2yO{43PDd3IN88US=>	MYnTRW5ITVJ?
C3A	NEDlZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7qToozUUN3ME2yO{45PDl4IN88US=>	M2HsU3NCVkeHUh?=
MDA-MB-157	NW\PUlB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zRNWlEPTB;MkeuPFc2OyEQvF2=	NWrt[HlIW0GQR1XS
KLE	NVjDd\|cyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPCTWM2OD1{OD6xNFU5KM7:TR?=	MXLTRW5ITVJ?
ES1	Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLtTWM2OD1{OD6xPFM5KM7:TR?=	MonuV2FPT0WU
CAL-120	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7hXZBtUUN3ME2yPE4{QTl7IN88US=>	NWL5SmNvW0GQR1XS
NCI-N87	NVnsTZhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXRdlBKSzVyPUK4MlUyODVizszN	M1;wT3NCVkeHUh?=
RPMI-8226	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LMcmlEPTB;MkmuNVg1OyEQvF2=	M37u[3NCVkeHUh?=
COR-L88	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHSTWM2OD1{OT6yOFE6KM7:TR?=	MoK5V2FPT0WU
UACC-893	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPmOG5UUUN3ME2yPU4{OTN5IN88US=>	M3[0THNCVkeHUh?=
C8166	NXf1RYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\WTWM2OD1{OT65PVk3KM7:TR?=	NHXaSm1USU6JRWK=
J82	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LwdmlEPTB;M{CuPFE1PyEQvF2=	Mnm5V2FPT0WU
PFSK-1	NVn3VYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTNSI5KSzVyPUOxMlA3PTlizszN	MYDTRW5ITVJ?
COLO-684	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrGTWM2OD1\|MT60N\|c1KM7:TR?=	NVe4ZoM3W0GQR1XS
CAL-72	MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjscXVyUUN3ME2zNU42PzJ7IN88US=>	NYPQXYsxW0GQR1XS
SNB75	M1jLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jhVWlEPTB;M{GuPFk4KM7:TR?=	NHPCR\|RUSU6JRWK=
MDA-MB-415	NX;XU2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LE[mlEPTB;M{GuPVc3OiEQvF2=	NVmzZoVMW0GQR1XS
SiHa	NITRZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELySVFKSzVyPUOyMlQ4OTFizszN	NX34VWRiW0GQR1XS
NCI-H1648	NHz3fIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLze4JFUUN3ME2zNk46OzR3IN88US=>	M3jJWHNCVkeHUh?=
EFO-21	NIiyXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLoTWM2OD1\|Mz6wNFUh\|ryP	MorYV2FPT0WU
HCC38	NGrDcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHGTWM2OD1\|Mz6zPFQyKM7:TR?=	MYLTRW5ITVJ?
IA-LM	M3r1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLHU4NkUUN3ME2zN{44QDh7IN88US=>	NHLFVotUSU6JRWK=
CTV-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXiWGNKSzVyPUOzMlk4QDZizszN	Moq3V2FPT0WU
NCI-H446	NWS4RpNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLVc\|BKSzVyPUO0MlI3QDlizszN	MVjTRW5ITVJ?
IST-SL1	Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF:4RVVKSzVyPUO0Mlc1ODhizszN	MWDTRW5ITVJ?
EW-22	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfkRoNvUUN3ME2zOE44PzV7IN88US=>	NUHTToR6W0GQR1XS
JEG-3	NHG4R\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLPdJBKSzVyPUO2MlE4PjZizszN	M2[xPHNCVkeHUh?=
LU-65	NFrrOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTYbZBiUUN3ME2zOk4zQTh3IN88US=>	MVPTRW5ITVJ?
NCI-H596	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\WdVVKSzVyPUO2Mlk2QTFizszN	MWLTRW5ITVJ?
KNS-81-FD	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TNWmlEPTB;M{euNVQ2KM7:TR?=	NHfXUlZUSU6JRWK=
NCI-H1793	M1Xuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4izSmlEPTB;M{euO\|A5PiEQvF2=	M{LWT3NCVkeHUh?=
NCI-H460	NGPWRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPYTWM2OD1\|OD6wPFc{KM7:TR?=	M4PJ[3NCVkeHUh?=
MPP-89	NFjaPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vLV2lEPTB;M{muOVg5PiEQvF2=	NIC3Z\|VUSU6JRWK=
D-542MG	MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrrTWM2OD1\|OT64OFM3KM7:TR?=	NGnPc4JUSU6JRWK=
JAR	M{LzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHlXIlKSzVyPUSwMlQ4ODVizszN	Mn7DV2FPT0WU
NCI-H209	NGjtT\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHlUZRKUUN3ME20NE43PzdizszN	NGm2e\|dUSU6JRWK=
G-402	MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjyeGZLUUN3ME20NU4{QTl\|IN88US=>	Ml7QV2FPT0WU
IST-MES1	M2jEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXobmpKUUN3ME20Nk4yQTN3IN88US=>	NW\tOWV2W0GQR1XS
Daoy	M3izNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHyyVVhKSzVyPUSyMlU1PzFizszN	MmS2V2FPT0WU
EW-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUX6S49OUUN3ME20N{4yOjFzIN88US=>	NULZWZJTW0GQR1XS
Saos-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LiZWlEPTB;NEOuNVU{PyEQvF2=	MUfTRW5ITVJ?
no-10	M{C0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\k[3NKSzVyPUSzMlE4ODJizszN	MYnTRW5ITVJ?
HCC1395	M1npfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3robGlEPTB;NEOuOFY1PCEQvF2=	NWXRZodTW0GQR1XS
HCE-4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLueYx5UUN3ME20N{44PjZ2IN88US=>	M2DLUXNCVkeHUh?=
EW-1	NEL3V4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XBeWlEPTB;NEOuPFA1QSEQvF2=	NG[5OJRUSU6JRWK=
OCUB-M	NFXqOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XudWlEPTB;NESuN\|Y{QCEQvF2=	NWLUNocyW0GQR1XS
IGR-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;0TWM2OD12ND60NVE2KM7:TR?=	M{HwcnNCVkeHUh?=
NCI-H1838	M1\TSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fLbWlEPTB;NESuOFM1QSEQvF2=	MnPXV2FPT0WU
NCI-H2405	M{HEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3jfVJKSzVyPUS0MlU{PCEQvF2=	MVPTRW5ITVJ?
GB-1	Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M372PGlEPTB;NESuO\|Q3OyEQvF2=	NWHQXW5WW0GQR1XS
MG-63	NFGyNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHz2PIhKSzVyPUS2MlA3QTZizszN	NHXx[5JUSU6JRWK=
KP-N-YN	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M365[GlEPTB;NE[uOFY4QSEQvF2=	NHPGfWZUSU6JRWK=
no-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXaTWM2OD12Nz6wNlQ1KM7:TR?=	NX\6N5BVW0GQR1XS
SW948	MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrCZpBzUUN3ME20O{4{Ozd5IN88US=>	M3HYeHNCVkeHUh?=
CAMA-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUOwSGQ1UUN3ME20O{4{PDN6IN88US=>	M{XJeHNCVkeHUh?=
HCC1187	MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vq[2lEPTB;NEeuOVEh\|ryP	MUXTRW5ITVJ?
D-392MG	M2LSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLiTWM2OD12Nz62OVE3KM7:TR?=	M2rRNHNCVkeHUh?=
647-V	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3wTWM2OD12OT6zOFE1KM7:TR?=	NVXmO2hiW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK1/2 / ERK1/2 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK1/2 in sympathetic neurons. Immunoblots were performed with whole cell extracts from sympathetic neurons maintained in the presence of NGF and left untreated or treated with PD184352 at 0.1, 1, 2 or 10 μM for 16 hours. Antibodies to detect total ERK1/2 and phospho-ERK1/2 were used. p-ERK5 / ERK5 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK5 in sympathetic neurons.	21762482
Growth inhibition assay	Cell viability; PubMed: 29989268 Cancer Sci Relative viability of DU145CR cells treated with PD184352 was significantly less than that of DU145 cells in WST assay.	29989268

In vivo

Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. ^[1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. ^[2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. ^[5]

Protocol

Kinase Assay: ^[2]	- Collapse MEK1 Assay: MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl₂ /2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research: ^[1]	- Collapse Cell lines: Colon 26 carcinoma cells Concentrations: 0.1-10 μM Incubation Time: 24 hours Method: Cells are planted seeded in T-75 cm ² flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: PTC cells in athymic mice Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water Dosages: 150 mg/kg Administration: Orally twice daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	96 mg/mL (200.55 mM)
	Ethanol	14 mg/mL (29.24 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 For best results, use promptly after mixing.	10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD184352 (CI-1040) SDF

Molecular Weight	478.67
Formula	C₁₇H₁₄ClF₂IN₂O₂
CAS No.	212631-79-3
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973, RG7420) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
PD0325901(Mirdametinib)

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features:Does not inhibit c-Raf phosphorylated MEK1.
Binimetinib (MEK162, ARRY-162, ARRY-438162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119, Bay 86-9766)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 78 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 78 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)